Carlson Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Carlson Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,600	Closed	-$775K	–	55
2024 Q4	$775K	Buy	+8,600	New	+$833K	0.46%	16
2024 Q1	–	Sell	-53,000	Closed	-$4.73M	–	156
2023 Q4	$4.73M	Sell	53,000 -33,400	-39%	-$2.48M	0.38%	71
2023 Q3	$6.31M	Buy	86,400 +24,000	+38%	+$1.92M	0.49%	60
2023 Q2	$5.19M	Sell	62,400 -4,900	-7%	-$410K	0.44%	65
2023 Q1	$5.13M	Buy	+67,300	New	+$5.58M	0.48%	56
2022 Q3	–	Sell	-39,900	Closed	-$2.96M	–	146
2022 Q2	$2.96M	Sell	39,900 -11,100	-22%	-$833K	0.2%	91
2022 Q1	$4.58M	Sell	51,000 -3,000	-6%	-$277K	0.31%	85
2021 Q4	$6.05M	Buy	54,000 +21,200	+65%	+$2.56M	0.35%	68
2021 Q3	$4.12M	Buy	32,800 +900	+3%	+$116K	0.22%	104
2021 Q2	$4.32M	Buy	+31,900	New	+$4.19M	0.21%	95

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Carlson Capital's XBI Position: Q1 2025 in Review

Carlson Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 8,600 shares — an estimated $775K sold.

Carlson Capital first reported a position in XBI in Q2 2021 and held it in 10 quarters. The position peaked at $6.31M in Q3 2023. 685 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

Carlson Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
Carlson Capital sold 8,600 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $775K.
Carlson Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 10 quarters.
Carlson Capital's State Street SPDR S&P Biotech ETF position peaked at $6.31M in Q3 2023.
685 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Carlson Capital's 13F filing for Q1 2025, filed 14 May 2025.